Latest news with #Anthem
Mint
3 days ago
- Business
- Mint
Anthem Biosciences share price gains after strong listing. Should you buy, sell or hold the stock?
Anthem Biosciences share price made a stellar debut in the Indian stock market today, July 21, after its initial public offering (IPO) received a strong demand. Anthem Biosciences shares listed at ₹ 723.05 apiece on the NSE, a premium of 26.85% over the issue price of ₹ 570 per share. On BSE, Anthem Biosciences share price opened at ₹ 723.10 apiece, higher by 26.86% from the IPO price. Anthem Biosciences is a manufacturer of specialised fermentation-based APIs, and its IPO was heavily oversubscribed. Anthem Biosciences IPO listing date was today, July 21, 2025. Anthem Biosciences IPO listing was in line with the Street estimates, as indicated by the grey market premium (GMP). Anthem Biosciences IPO GMP today, and analysts had signalled a strong debut of shares. Here's what investors should do after Anthem Biosciences' share listing today. Mahesh M. Ojha, AVP - Research & Business Development at Hensex Securities, advises short-term investors who were allotted shares to consider booking partial profits as he believes over 25% gain at listing is substantial, and booking gains allows for risk management. 'Long-term investors should focus on the company's growth roadmap. Anthem has strong fundamentals, but future performance will depend on margin sustainability, innovation pipeline, and global client growth. For investors who missed the IPO, it would be wise to wait for a few trading sessions. Once the stock stabilises, it may offer a better entry point based on earnings visibility and peer comparison,' Ojha said. According to Prashanth Tapse, Sr. VP Research at Mehta Equities, Anthem Biosciences made a healthy debut, broadly in line with expectations, reflecting strong investor appetite. 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility. The ability to consistently deliver earnings growth, in line with street expectations, further supports its valuation,' Tapse said. Hence, looking at its all financial as well as sectorial, he recommends investors to 'Hold' Anthem Biosciences shares for a long-term perspective. 'For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, justifying the listing. In the short term, we foresee ₹ 900 as the target for Anthem shares, while long-term investors can hold it for ₹ 1,000 and above. Non-allottees can wait for some volatility to settle in price, and in any case, if the stock is available around ₹ 650-680, it can be considered a good range to accumulate with a long-term vision,' Tapse said. Shivani Nyati, Head of Wealth at Swastika Investmart, recommends investors to secure partial profits and retain the remainder with a stop-loss set at ₹ 650. Anthem Biosciences IPO was open from July 14 to July 16. The IPO was subscribed 63.86 times in total, as per the NSE subscription data. The retail portion was booked 5.64 times, while the Non-Institutional Investors (NII) segment was subscribed 42.36 times. The Qualified Institutional Buyers (QIBs) category received 182.65 times subscription. At 12:25 PM, Anthem Biosciences' share price was trading at ₹ 728.90 apiece on the BSE, up by 0.80% from its listing price, and up 27.88% from its issue price.
Mint
3 days ago
- Business
- Mint
Anthem Biosciences share price gains after strong listing. Should you buy, sell of hold the stock?
Anthem Biosciences share price made a stellar debut in the Indian stock market today after its initial public offering (IPO) received strong demand. Anthem Biosciences shares were listed at ₹ 723.05 apiece on the NSE, a premium of 26.85% to the issue price of ₹ 570 per share. On BSE, Anthem Biosciences share price opened at ₹ 723.10 apiece, higher by 26.86% from the IPO price. Anthem Biosciences is a manufacturer of specialized fermentation-based APIs and its IPO was heavily oversubscribed. Anthem Biosciences IPO listing date was today, 21 July 2025. Anthem Biosciences IPO listing was in line with the Street estimates as indicated by the grey market premium (GMP). Anthem Biosciences IPO GMP today ahead of the listing and analysts had signalled a strong debut of shares. Here's what investors should do after Anthem Biosciences share listing today. Mahesh M. Ojha, AVP - Research & Business Development at Hensex Securities Pvt. Ltd. advises short-term investors who were allotted shares to consider booking partial profits as he believes over 25% gain at listing is substantial, and booking gains allows for risk management. 'Long-term investors should focus on the company's growth roadmap. Anthem has strong fundamentals, but future performance will depend on margin sustainability, innovation pipeline, and global client growth. For investors who missed the IPO, it would be wise to wait for a few trading sessions. Once the stock stabilizes, it may offer a better entry point based on earnings visibility and peer comparison,' Ojha said. According to Prashanth Tapse, Sr Vp Research & Research Analyst at Mehta Equities Ltd, Anthem Biosciences made a healthy debut, broadly in line with expectations, reflecting strong investor appetite. 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility. The ability to consistently deliver earnings growth, in line with street expectations, further supports its valuation,' Tapse said. Hence, looking at its all financial as well as sectorial, he recommends investors to 'Hold' Anthem Biosciences shares for long-term perspective. 'For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, justifying the listing. Short term we foresee ₹ 900 as target while long term investors can hold it for ₹ 1,000 and above. Non allottees wait for some volatility to settle in price and in any case if the stock is available around ₹ 650-680, can be considered a good range to accumulate with long term vision,' Tapse said. Shivani Nyati, Head of Wealth at Swastika Investmart Ltd. recommends investors to secure partial profits and retain the remainder with a stop-loss set at ₹ 650. Anthem Biosciences IPO was open from July 14 to July 16. The IPO was subscribed 63.86 times in total, as per the NSE subscription data. The retail portion was booked 5.64 times, while the Non Institutional Investors (NII) segment was subscribed 42.36 times. The Qualified Institutional Buyers (QIBs) category received 182.65 times subscription. At 12:25 PM, Anthem Biosciences share price was trading at ₹ 728.90 apiece on the BSE, up by 0.80% from its listing price, and up 27.88% from its issue price. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Economic Times
3 days ago
- Business
- Economic Times
Anthem Biosciences shares rally 3% after healthy listing. Should you buy now?
Live Events About Anthem Biosciences Anthem Biosciences' financial performance (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel The shares of the newly listed Anthem Biosciences rallied 3.3% on the BSE to their intraday high of Rs 746.70 in Monday's trade, after listing at a healthy premium of 27% over its IPO the IPO investors are already sitting on an overall gain of 31%.Anthem Biosciences made a strong debut on the stock market with a listing gain of approximately 26.84% over its issue price of Rs 570, getting listed at around Rs 723. The IPO garnered massive investor interest, achieving an impressive overall subscription of 67.42 times, reflecting high demand across all issue had no fresh component, and the proceeds will go entirely to selling shareholders. Anchor investors had already pumped in Rs 1,016 crore before the IPO a bumper listing on the bourses, should you buy the shares of Anthem Biosciences?Shivani Nyati, Head of Wealth at Swastika Investmart , advises investors to secure partial profits and retain the remainder with a stop-loss set at Rs 650.'The company is one of the leading global players in the innovation-driven, technology-focused CRDMO segment . It enjoys a niche place in the segment and leads the pack of players. The company marked steady growth in its top lines for the reported periods,' noted Prashanth Tapse, Senior VP (Research) at Mehta Equities, highlighted, 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility,' while recommending a 'hold' rating on the stock.'Looking at its all financial as well as sectorial, we recommend investors to 'HOLD' the Anthem Biosciences for a long-term perspective. For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, which justifies the listing,' he the short term, he foresees Rs 900 as the target, while the long-term investors can hold it for Rs 1,000 and the non-allottees, it is advised to wait for some volatility to settle in price and in case, if the stock is available around Rs 650-680, it can be considered as a good range to accumulate with long-term in 2006, Anthem operates across the drug development lifecycle—discovery, development, and commercial manufacturing—for both small molecules and 196 projects underway, a global customer base across 44 countries, and a growing portfolio of fermentation-based APIs and specialty ingredients, the company has carved a niche in India's pharma value FY25, Anthem reported a 30% rise in revenue to Rs 1,930 crore and a 23% growth in net profit to Rs 451 crore. EBITDA came in at Rs 684 crore with a strong margin of nearly 37%, while debt levels remained low.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Time of India
3 days ago
- Business
- Time of India
Anthem Biosciences shares rally 3% after healthy listing. Should you buy now?
Live Events About Anthem Biosciences Anthem Biosciences' financial performance (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel The shares of the newly listed Anthem Biosciences rallied 3.3% on the BSE to their intraday high of Rs 746.70 in Monday's trade, after listing at a healthy premium of 27% over its IPO the IPO investors are already sitting on an overall gain of 31%.Anthem Biosciences made a strong debut on the stock market with a listing gain of approximately 26.84% over its issue price of Rs 570, getting listed at around Rs 723. The IPO garnered massive investor interest, achieving an impressive overall subscription of 67.42 times, reflecting high demand across all issue had no fresh component, and the proceeds will go entirely to selling shareholders. Anchor investors had already pumped in Rs 1,016 crore before the IPO a bumper listing on the bourses, should you buy the shares of Anthem Biosciences?Shivani Nyati, Head of Wealth at Swastika Investmart , advises investors to secure partial profits and retain the remainder with a stop-loss set at Rs 650.'The company is one of the leading global players in the innovation-driven, technology-focused CRDMO segment . It enjoys a niche place in the segment and leads the pack of players. The company marked steady growth in its top lines for the reported periods,' noted Prashanth Tapse, Senior VP (Research) at Mehta Equities, highlighted, 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility,' while recommending a 'hold' rating on the stock.'Looking at its all financial as well as sectorial, we recommend investors to 'HOLD' the Anthem Biosciences for a long-term perspective. For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, which justifies the listing,' he the short term, he foresees Rs 900 as the target, while the long-term investors can hold it for Rs 1,000 and the non-allottees, it is advised to wait for some volatility to settle in price and in case, if the stock is available around Rs 650-680, it can be considered as a good range to accumulate with long-term in 2006, Anthem operates across the drug development lifecycle—discovery, development, and commercial manufacturing—for both small molecules and 196 projects underway, a global customer base across 44 countries, and a growing portfolio of fermentation-based APIs and specialty ingredients, the company has carved a niche in India's pharma value FY25, Anthem reported a 30% rise in revenue to Rs 1,930 crore and a 23% growth in net profit to Rs 451 crore. EBITDA came in at Rs 684 crore with a strong margin of nearly 37%, while debt levels remained low.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
News18
3 days ago
- Business
- News18
Anthem Biosciences IPO Lists At 26.8% Premium: Should You Buy, Hold, Or Sell?
Anthem Biosciences Share Price: Its shares were listed at Rs 723 apiece on the BSE, a premium of 26.85 per cent as against the IPO issue price of Rs 570. Anthem Biosciences Share Price: Anthem Biosciences Ltd made a strong stock market debut on Monday, July 21. Its shares were listed at Rs 723 apiece on the BSE, a premium of 26.85 per cent as against the IPO issue price of Rs 570. The share prices rose further and were trading at Rs 730 apiece, as of 10:14 am. The stock was also listed at Rs 723.05 apiece on the NSE. Its market capitalisation (m-cap) stood at Rs 40,997.53 crore. Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organisation (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It also manufactures and sells complex specialised fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars. Anthem Biosciences IPO Listing: Should You Buy, Hold Or Sell? Brokerages remain largely optimistic about Anthem Biosciences, citing its strong financial track record, niche positioning in the CRDMO space, and robust pipeline. However, a few have flagged concerns over valuations and margin pressures. However, it cautioned that growth is dependent on the success of pipeline molecules and regulatory compliance, among other risks. Anand Rathi Shares & Stock Broking noted that Anthem is 'positioned to cater in CROs and CRDMO segment — the crucial players in the pharma and biotechnology industries — wherein it is being niche player with high entry barriers through its differentiated FFS model, long-term relationship, strong R&D, innovation and technology-driven approach." The brokerage firm added that the company has outperformed peers in profitability and is likely to maintain that edge. Anthem Biosciences IPO: More Info The IPO was open for public subscription between July 14 and July 16. It received a strong 67.42 times subscription, garnering bids for 2,81,49,30,794 shares as against the 4,17,50,321 shares on offer. The retail and NII participation stood at 5.98x and 44.70x, respectively. The QIB category received a 192.80x subscription. The price band of the mainboard IPO, which aimed to raise Rs 3,395 crore, was fixed in the range of Rs 540 to Rs 570. The IPO is entirely an offer-for-sale (OFS). So, the company will not receive any funds from the issue and the proceeds will go to the selling shareholders. view comments Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
